The over-expression of ANXA5 was observed in various tumor types such as breast cancers, hepatocarcinoma, CRC, cervical cancer, gastric cancer, pancreatic adenocarcinoma, prostate cancer, bladder cancer and nasopharyngeal carcinoma and has been reported to be involved in drug resistance in these cancers [28]. Here, ANXA5 is linked to nasopharyngeal carcinoma.